These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21204763)

  • 41. Studies on efficacy of a novel 177Lu-labeled porphyrin derivative in regression of tumors in mouse model.
    Sarma HD; Das T; Banerjee S; Venkatesh M; Vidyasagar PB; Mishra KP
    Curr Radiopharm; 2011 Apr; 4(2):150-60. PubMed ID: 22191655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
    Vera DR; Eigner S; Henke KE; Lebeda O; Melichar F; Beran M
    Nucl Med Biol; 2012 Jan; 39(1):3-13. PubMed ID: 21958849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of DOTA-Chelators on the Antitumor Activity of
    Wojdowska W; Karczmarczyk U; Balog L; Sawicka A; Pöstényi Z; Kovács-Haász V; Polyák A; Laszuk E; Mikołajczak R; Garnuszek P
    Cancer Biother Radiopharm; 2020 Oct; 35(8):558-562. PubMed ID: 32255676
    [No Abstract]   [Full Text] [Related]  

  • 44. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
    Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
    Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
    Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
    J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
    Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
    Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
    Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR
    Cancer Res; 2011 Feb; 71(3):1009-18. PubMed ID: 21245097
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Demonstration of dose dependent cytotoxic activity in SW480 colon cancer cells by ¹⁷⁷Lu-labeled siRNA targeting IGF-1R.
    Fathi M; Taghikhani M; Ghannadi-Maragheh M; Yavari K
    Nucl Med Biol; 2013 May; 40(4):529-36. PubMed ID: 23618769
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors.
    Chen J; Linder KE; Cagnolini A; Metcalfe E; Raju N; Tweedle MF; Swenson RE
    Appl Radiat Isot; 2008 Apr; 66(4):497-505. PubMed ID: 18178448
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis of (68)Ga-labeled NOTA-RGD-GE11 heterodimeric peptide for dual integrin and epidermal growth factor receptor-targeted tumor imaging.
    Yu HM; Chen JH; Lin KL; Lin WJ
    J Labelled Comp Radiopharm; 2015 Jun; 58(7):299-303. PubMed ID: 25997858
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
    Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
    Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preclinical evaluation of new GnRH-I receptor radionuclide therapy with
    Zoghi M; Attar Nosrati S; Rogni F; Shirvani G; Johari Daha F
    J Labelled Comp Radiopharm; 2019 Jun; 62(7):310-320. PubMed ID: 31033025
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and characterization of nitroimidazole derivatives for 68Ga-labeling and testing in tumor xenografted mice.
    Hoigebazar L; Jeong JM; Choi SY; Choi JY; Shetty D; Lee YS; Lee DS; Chung JK; Lee MC; Chung YK
    J Med Chem; 2010 Sep; 53(17):6378-85. PubMed ID: 20690646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists.
    Dijkgraaf I; Kruijtzer JA; Frielink C; Soede AC; Hilbers HW; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
    Nucl Med Biol; 2006 Nov; 33(8):953-61. PubMed ID: 17127167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.
    Miao Y; Fisher DR; Quinn TP
    Nucl Med Biol; 2006 Aug; 33(6):723-33. PubMed ID: 16934691
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with (177)Lu and Conjugated to Peptides.
    Ferro-Flores G; Ocampo-García BE; Santos-Cuevas CL; de María Ramírez F; Azorín-Vega EP; Meléndez-Alafort L
    Curr Radiopharm; 2015; 8(2):150-9. PubMed ID: 25771363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide.
    Chen X; Park R; Tohme M; Shahinian AH; Bading JR; Conti PS
    Bioconjug Chem; 2004; 15(1):41-9. PubMed ID: 14733582
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An improved method of 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK).
    Lee YS; Jeong JM; Kim HW; Chang YS; Kim YJ; Hong MK; Rai GB; Chi DY; Kang WJ; Kang JH; Lee DS; Chung JK; Lee MC; Suh YG
    Nucl Med Biol; 2006 Jul; 33(5):677-83. PubMed ID: 16843843
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stability analysis of glutamic acid linked peptides coupled to NOTA through different chemical linkages.
    Lang L; Ma Y; Kiesewetter DO; Chen X
    Mol Pharm; 2014 Nov; 11(11):3867-74. PubMed ID: 24533430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
    Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
    J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.